Effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock

被引:278
作者
Pontes-Arruda, Alessandro [1 ]
Albuquerque Aragao, Afra Maria
Albuquerque, Juliana Deusdara
机构
[1] Fernandes Tavora Hosp, Dept Intens Care, Fortaleza, Ceara, Brazil
[2] Latin Amer Sepsis Inst, Sao Paulo, Brazil
[3] Antonio Prudente Hosp, Dept Nutr, Fortaleza, Ceara, Brazil
关键词
severe sepsis; fish oil; borage oil; randomized; enteral nutrition; immunomodulation;
D O I
10.1097/01.CCM.0000234033.65657.B6
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Enteral diets enriched with eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and antioxidants have previously been shown to improve outcomes in patients with acute respiratory distress syndrome. Several studies using animal models of sepsis demonstrate that enteral nutrition enriched with omega-3 fatty acids reduces mortality rate. This study investigated whether an enteral diet enriched with EPA, GLA, and antioxidant vitamins can improve outcomes and reduce 28-day all-cause mortality in patients with severe sepsis or septic shock requiring mechanical ventilation. Design: Prospective, double-blind, placebo-controlled, randomized trial. Setting: Three different intensive care units of a tertiary hospital in Brazil. Patients: The study enrolled 165 patients. Interventions: Patients were randomized to be continuously tube-fed with either a diet enriched with EPA, GLA, and elevated antioxidants or an isonitrogenous and isocaloric control diet, delivered at a constant rate to achieve a minimum of 75% of basal energy expenditure x 1.3 during a minimum of 4 days. Measurements and Main Results: Patients were monitored for 28 days. Patients who were fed with the study diet experienced a significant reduction in mortality rate compared with patients fed with the control diet, the absolute mortality reduction amounting to 19.4% (p = .037). The group who received the study diet also experienced significant improvements in oxygenation status, more ventilator-free days (13.4 +/- 1.2 vs. 5.8 +/- 1.0, p < .001), more intensive care unit (ICU)-free days (10.8 +/- 1.1 vs. 4.6 +/- 0.9, p < .001), and a lesser development of new organ dysfunctions (P <.001). Conclusions: In patients with severe sepsis or septic shock and requiring mechanical ventilation and tolerating enteral nutrition, a diet enriched with EPA, GLA, and elevated antioxidants contributed to better ICU and hospital outcomes and was associated with lower mortality rates.
引用
收藏
页码:2325 / 2333
页数:9
相关论文
共 45 条
[1]  
ALSAADY NM, 1989, INTENS CARE MED, V15, P290
[2]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[3]   DIETARY OMEGA-3-FATTY-ACIDS DECREASE MORTALITY AND KUPFFER CELL PROSTAGLANDIN-E2 PRODUCTION IN A RAT MODEL OF CHRONIC SEPSIS [J].
BARTON, RG ;
WELLS, CL ;
CARLSON, A ;
SINGH, R ;
SULLIVAN, JJ ;
CERRA, FB .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1991, 31 (06) :768-774
[4]   Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis [J].
Bernard, GR ;
Margolis, BD ;
Shanies, HM ;
Ely, EW ;
Wheeler, AP ;
Levy, H ;
Wong, K ;
Wright, TJ ;
Ahmed, M ;
Albertson, T ;
Anas, N ;
Astiz, M ;
Bacon, A ;
Bandi, V ;
Booth, F ;
Bray, W ;
Brilli, R ;
Carlson, R ;
Cheatham, M ;
Conrad, S ;
Cooney, R ;
Cox, M ;
Dolich, M ;
Dries, D ;
Fang, R ;
Forse, R ;
Fricker, R ;
Givens, C ;
Gomez, C ;
Gottlieb, J ;
Graham, D ;
Cropper, I ;
Cross, T ;
Harrison, N ;
Kearl, R ;
Kearney, P ;
Kinasewitz, G ;
Kruse, J ;
Lamberti, J ;
Levy, M ;
Light, R ;
Lin, L ;
Lisco, S ;
Lo, T ;
Linda, L ;
Lodato, R ;
Malave, L ;
Martinez, A ;
Mastuschak, G ;
McDermott, L .
CHEST, 2004, 125 (06) :2206-2216
[5]   THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[6]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[7]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[8]   Sir Isaac Newton, sepsis, SIRS, and CARS [J].
Bone, RC .
CRITICAL CARE MEDICINE, 1996, 24 (07) :1125-1128
[9]   Current clinical options for the treatment and management of acute respiratory distress syndrome [J].
Bulger, EM ;
Jurkovich, GJ ;
Gentilello, LM ;
Maier, RV .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2000, 48 (03) :562-572
[10]  
Bulger EM, 1997, ARCH SURG-CHICAGO, V132, P1337